Advertisement

Topics

Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA

11:30 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-FDA grants Priority Review of the application and sets action date of February 28, 2018- -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copi...

Other Sources for this Article

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
or
Eric Rojas, 617-961-7205
or
Zach Barber, 617-341-6470
or
Media:
North America:
Megan Goulart, + 1-617-341-6992
mediainfo@vrtx.com
or
Europe & Australia:
Rebecca Hunt, +44 7718 962690

NEXT ARTICLE

More From BioPortfolio on "Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...